Clinical Pearls and Advances in Molecular Researches of Epilepsy-Associated Tumors
- Author:
Ji Hoon PHI
1
;
Seung Ki KIM
Author Information
- Publication Type:Review
- Keywords: Brain neoplasms; Seizures; Epilepsy; Glioma; Classification
- MeSH: Age of Onset; Astrocytoma; Biology; Brain; Brain Neoplasms; Classification; Epilepsy; Ganglioglioma; Glioma; Humans; Molecular Targeted Therapy; Neoplasms, Neuroepithelial; Seizures; Temporal Lobe
- From:Journal of Korean Neurosurgical Society 2019;62(3):313-320
- CountryRepublic of Korea
- Language:English
- Abstract: Brain tumors are the second most common type of structural brain lesion that causes chronic epilepsy. Patients with low-grade brain tumors often experience chronic drug-resistant epilepsy starting in childhood, which led to the concept of long-term epilepsy-associated tumors (LEATs). Dysembryoplastic neuroepithelial tumor and ganglioglioma are representative LEATs and are characterized by young age of onset, frequent temporal lobe location, benign tumor biology, and chronic epilepsy. Although highly relevant in clinical epileptology, the concept of LEATs has been criticized in the neuro-oncology field. Recent genomic and molecular studies have challenged traditional views on LEATs and low-grade gliomas. Molecular studies have revealed that low-grade gliomas can largely be divided into three groups : LEATs, pediatric-type diffuse low-grade glioma (DLGG; astrocytoma and oligodendroglioma), and adult-type DLGG. There is substantial overlap between conventional LEATs and pediatric-type DLGG in regard to clinical features, histology, and molecular characteristics. LEATs and pediatric-type DLGG are characterized by mutations in BRAF, FGFR1, and MYB/MYBL1, which converge on the RAS-RAF-MAPK pathway. Gene (mutation)-centered classification of epilepsy-associated tumors could provide new insight into these heterogeneous and diverse neoplasms and may lead to novel molecular targeted therapies for epilepsy in the near future.
